We are a diversified healthcare group that is developing, investing in and delivering a range of exciting new technologies and leading edge medical devices that have the potential to make a real difference to the outcomes and quality of life of patients around the globe.
Avoid the “variability” of the elastomeric technology. ambIT® infusion pumps require less intervention, minimise risk of dosing errors and ensure that pain is controlled.Read More
Admedus has a portfolio of technology at various stages of development that target areas of significant clinical need. R and D projects, medical technologies in clinical trial, products pending market approval and a strong distribution business supplying medical devices to the healthcare market.Read More
Our immunotherapies R&D partnership with Professor Ian Frazer is researching and commercialising new vaccines to prevent diseaseRead More
Lead by Professor Ian Frazer our therapeutic vaccines now in Phase I trial will treat a range of infectious diseases and cancersRead More
First of our Regenerative Tissue products, CardioCel®, a cardiovascular patch, available in Europe and seeking global approval.Read More
Our sales and distribution business is taking innovative infusion products to the Australasian healthcare market and making a difference to patientsRead More
Admedus are focused on bringing leading medical products and technologies to the global healthcare market
Admedus are being recognised as a part of the future of medical device manufacturing
On 12 May 2014 Admedus announced a Share Purchase Plan (SPP) open to eligible shareholders.
Introducing the Chroma smart pumps - the next generation in Whole-of-Hospital infusion solutions by Admedus
A short animation demonstrating how CardioCel® is used to repair defects in the human heart.